Communiqués Cue Biopharma, Inc.

Actions

CUE

US22978P1066

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,24 ^USD	-11,43%		-8,15%	-53,03%

07/06	Cue Biopharma, Inc. nomme Michael J. Fox au conseil d'administration et au comité des rémunérations	CI
09/05	Cue Biopharma, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting	04/06	GL
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting	04/06	AQ
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024	03/06	GL
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024	03/06	AQ
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05	GL
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit	08/05	GL
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference	07/05	GL
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04	GL
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights	08/04	GL
Cue Biopharma to Host Business Update Call and Webcast	02/04	GL
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium	29/02	GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02	GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02	AQ
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23/11	AQ
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit	22/11	GL
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights	09/11	GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11	GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11	AQ
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023	03/11	GL
Cue Biopharma to Host Business Update Call and Webcast	02/11	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cue Biopharma, Inc.

Actions

CUE

US22978P1066

Communiqués

Filtres